Sector News

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

February 2, 2015
Life sciences
(Reuters) – India’s Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.
 
Sun Pharmaceutical said in April that it had agreed to buy the Indian generic drugmaker from its current owner, Japan’s Daiichi Sankyo Co, for $3.2 billion.
 
Ranbaxy has been involved in a wrangle with the U.S. Food and Drug Administration, which has barred a range of its medicines from the United States after finding that some of the company’s plants did not meet U.S. standards.
 
The FTC, whose job is to ensure that anti-monopoly laws are enforced, did not weigh in on the safety issue but said it would allow the transaction if Ranbaxy sold its interests in generic minocycline tablets and capsules to generic maker Torrent Pharmaceuticals Ltd, which is also based in India.
 
The medicine is commonly used to treat pneumonia, urinary tract infections and acne.
 
Ranbaxy is one of three companies to sell the antibacterial drug, and Sun is expected to begin selling the medicines soon, the FTC said in a statement.
 
(Reporting by Diane Bartz; Editing by Jonathan Oatis)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend